Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
FDA Approves Genentech's Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
01:00am, Friday, 05'th Jul 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) has approved the Vabysmo®
FDA approves Roche's Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
01:00am, Friday, 05'th Jul 2024
Basel, 05 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6.0 mg single-dose prefilled syr
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
10:25am, Thursday, 04'th Jul 2024
Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
Roche to halt trial in latest setback for lung cancer immunotherapy
04:07am, Thursday, 04'th Jul 2024
Roche will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck & Co , casting further doubt on the drug candidate p
Basel, 04 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembr
Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs
05:16am, Tuesday, 02'nd Jul 2024
Roche (RHHBY) gets CHMP recommendation for a label expansion of ophthalmology drug Vabysmo (faricimab) and PiaSky (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria.
Roche's Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
07:15am, Friday, 28'th Jun 2024
Basel, 28 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for t
CHMP recommends EU approval of Roche's PiaSky for people with PNH, a rare, life-threatening blood condition
07:00am, Friday, 28'th Jun 2024
Basel, 28 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion
Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
01:00am, Thursday, 27'th Jun 2024
Basel, 27 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the World Health Organization (WHO) has awarded the cobas® HPV test prequalification designations for use on the cobas®
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
01:50pm, Tuesday, 25'th Jun 2024
Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also u
OCREVUS® subcutaneous (SC) injection offers a new 10-minute administration with comparable efficacy and safety to intravenous (IV) infusion Provides an additional treatment option without the need fo
Basel, 25 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for OCREVUS® (ocrelizumab) subcutaneous (SC) for the treatmen
Will Roche Stock Rebound To Its 2022 Highs Of $50?
10:00am, Monday, 24'th Jun 2024
The stock price of Roche (OTCMKTS: RHHBY) trades at $35 per share, about 33% below its peak level of over $53 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48%
Basel, 24 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its new analytical units, cobas® c 703 and cobas® ISE neo, for the cobas® pro integrated solutions, in countri
US FDA approves Roche's drug for a chronic blood disorder
04:41pm, Friday, 21'st Jun 2024
The U.S. Food and Drug Administration on Thursday approved Roche's drug for a chronic blood disorder, the Swiss drugmaker said.
